Profile picture

Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)
Membership: ESC Professional Member HFA Member
Follow
Biography
Dr. Greene is a heart failure cardiologist and Associate Professor in the Division of Cardiology and Duke Clinical Research Institute, at the Duke University School of Medicine. Dr. Greene’s research focuses on improving quality of care and outcomes for patients with heart failure. He has been a co-investigator and co-author of multiple national and international heart failure trials studying medical therapies for heart failure, including the ASTRONAUT, SOCRATES-Reduced, COMPOSE, TRANSFORM-HF, and VELOCITY trials. He has also led multiple analyses from national registries characterizing the quality of heart failure care in U.S. and global clinical practice, including studies leveraging the CHAMP-HF registry, American Heart Association’s Get With The Guidelines Heart Failure registry, the VICTORIA registry, and the CARE-HK in HF registry. Dr. Greene’s collaborative work has led to more than 400 publications in peer-reviewed journals.
Logo ESC

Contributor content

Cardiovascular-kidney-metabolic overlap in patients hospitalized for heart failure across the ejection fraction spectrum
Presentation
Cardiovascular-kidney-metabolic overlap in patients hospitalized for heart failure across the ejection fraction spectrum
Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study
Presentation
Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study
Early empagliflozin initiation after hospitalization for heart failure in the United States: a target trial emulation
Presentation
Early empagliflozin initiation after hospitalization for heart failure in the United States: a target trial emulation
Outpatient clinic visits before and after hospitalizations for heart failure with and without transthyretin amyloid cardiomyopathy: from the TTRanslate-HF program
Presentation
Outpatient clinic visits before and after hospitalizations for heart failure with and without transthyretin amyloid cardiomyopathy: from the TTRanslate-HF program
Q&A
Presentation
Building momentum: reviewing current treatment patterns and guideline-directed medical therapy implementation to optimise heart failure management
Presentation
Building momentum: reviewing current treatment patterns and guideline-directed medical therapy implementation to optimise heart failure management
Beyond the textbook: patient voices and expert-led practical management for SGLT2 inhibitor implementation in heart failure
Presentation
Beyond the textbook: patient voices and expert-led practical management for SGLT2 inhibitor implementation in heart failure
Beyond the textbook: patient voices and expert-led practical management for SGLT2 inhibitor implementation in heart failure
Presentation
Beyond the textbook: patient voices and expert-led practical management for SGLT2 inhibitor implementation in heart failure
Discussion and Q&A: where do we go from here?
Presentation
Discussion and Q&A: where do we go from here?
Cardiovascular death: if this isn't failure, what is?
Presentation
Cardiovascular death: if this isn't failure, what is?

ESC 365 is supported by